anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: SODIUM FLUORIDE
Trial phase: Phase 2
ATC code: A01AA01 | A01AA51 | A12CD01 | V09IX06
SMILES: [F-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Subjects will be asked to rinse/gargle one time with 10 mL of Povidone-iodine 0.5% antiseptic mouth rinse for 30 seconds.

Mouth rinse: Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
Eligibility criteria:
Inclusion Criteria:

Able and willing to provide informed consent prior to initiation of study procedures.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male or female, aged 18 years and older.
Clinical diagnosis of COVID-19 infection confirmed with a positive point of care test.
Confirmed diagnosis within 5 days of baseline visit (within 5 days of COVID-19 test) and at least one clinical COVID-19 symptom [*Signs and symptoms of COVID-19 present at illness onset vary, but over the course of the disease, most people will experience the following: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste of smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea.]
Presents with a minimum of six natural teeth.
Ability to rinse/gargle with study products.
Not using mouth rinse/gargling solutions at the time of enrollment.
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics, including hydroxychloroquine) at time of enrollment.
Ability to participate in the study and come to site during Phase I of the study for collection of swabs and saliva.
Willing to use an acceptable method of birth control throughout duration of the study. Acceptable methods include hormonal contraceptives, barrier methods, abstinence, or other effective methods approved by the PI.
If continuing to Phase II of the trial, ability to continue using study products for 1 week (+ 3 days). (Participants do not have to agree to participate in Phase II in order to participate in Phase I.)
If continuing to Phase II of the trial, agree to receive text messages/phone calls containing questionnaires regarding compliance and use of study product, and reminders, able to complete virtual follow-up study visit for collection of outcomes data.

Exclusion Criteria:

Individuals receiving antiviral medications
Pregnant or breastfeeding women (for premenopausal women of childbearing potential, pregnancy status to be confirmed through a urine pregnancy test during the study visit)
Inability to comply with study protocol
Having an allergy to any of the study mouthwash ingredients
Having any thyroid condition.
Presents with a current suspicious oral lesion at the examiner's discretion, and/or currently undergoing radiation therapy for head or neck cancer, and/or has received radiation therapy to the head or neck (including radioactive iodine therapy).
Intervention: SODIUM FLUORIDE
Trial phase: Phase 2
ATC code: A01AA01 | A01AA51 | A12CD01 | V09IX06
SMILES: [F-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Subjects will be asked to rinse/gargle one time with 10 mL of placebo mouth rinse for 30 seconds.

Mouth rinse: Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
Eligibility criteria:
Inclusion Criteria:

Able and willing to provide informed consent prior to initiation of study procedures.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male or female, aged 18 years and older.
Clinical diagnosis of COVID-19 infection confirmed with a positive point of care test.
Confirmed diagnosis within 5 days of baseline visit (within 5 days of COVID-19 test) and at least one clinical COVID-19 symptom [*Signs and symptoms of COVID-19 present at illness onset vary, but over the course of the disease, most people will experience the following: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste of smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea.]
Presents with a minimum of six natural teeth.
Ability to rinse/gargle with study products.
Not using mouth rinse/gargling solutions at the time of enrollment.
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics, including hydroxychloroquine) at time of enrollment.
Ability to participate in the study and come to site during Phase I of the study for collection of swabs and saliva.
Willing to use an acceptable method of birth control throughout duration of the study. Acceptable methods include hormonal contraceptives, barrier methods, abstinence, or other effective methods approved by the PI.
If continuing to Phase II of the trial, ability to continue using study products for 1 week (+ 3 days). (Participants do not have to agree to participate in Phase II in order to participate in Phase I.)
If continuing to Phase II of the trial, agree to receive text messages/phone calls containing questionnaires regarding compliance and use of study product, and reminders, able to complete virtual follow-up study visit for collection of outcomes data.

Exclusion Criteria:

Individuals receiving antiviral medications
Pregnant or breastfeeding women (for premenopausal women of childbearing potential, pregnancy status to be confirmed through a urine pregnancy test during the study visit)
Inability to comply with study protocol
Having an allergy to any of the study mouthwash ingredients
Having any thyroid condition.
Presents with a current suspicious oral lesion at the examiner's discretion, and/or currently undergoing radiation therapy for head or neck cancer, and/or has received radiation therapy to the head or neck (including radioactive iodine therapy).
Intervention: PCSK9 macrocyclic peptide inhibitor MK-0616
Trial phase: Phase 2
SMILES: COc1ccc(CC(NC(=O)C(NC(=O)C2C3CCN2C(=O)C(Cc2cn(Cc4cn(-c5cc(C)cc(C)c5)nn4)c4ccc(F)cc24)NC(=O)C(NC(=O)C(C)NC(=O)C(CNC(=O)CCOCCOCC[N+](C)(C)C)NC(=O)CCS)Cc2cccc(c2)CC=CCO3)C(C)O)C(=O)N2CCCC2(C)C(=O)NCCS)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 77
Group description: Participants received 6 mg of MK-0616 orally QD for 8 weeks
Eligibility criteria:
Inclusion Criteria:

History of clinical atherosclerotic cardiovascular disease (ASCVD), or has an ASCVD risk equivalent and/or a 10-year risk of having an ASCVD event ≥5.0%, AND has a corresponding LDL-C that falls within the protocol-specified range at screening.
Treatment with a stable dose of one or more lipid-lowering therapies for ≥30 days before screening, or has not received treatment with any lipid-lowering therapy for ≥30 days before screening.
A female participant is not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance during the intervention period and for at least 8 weeks after the last dose of study intervention.

Exclusion Criteria:

History of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria.
History of nephrotic syndrome.
History of unstable angina, a myocardial infarction, percutaneous transluminal coronary angioplasty, transient ischemic attack, or stroke within 3 months before Screening.
Has poorly controlled diabetes mellitus, defined as hemoglobin A1C (A1C) ≥9.0% at Screening.
History of malignancy ≤3 years before screening, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, which have no timeframe limitations relative to screening.
Currently participating in or has previously participated in an interventional clinical study within 3 months before Screening.
Has moderate or greater renal insufficiency.
Intervention: PCSK9 macrocyclic peptide inhibitor MK-0616
Trial phase: Phase 2
SMILES: COc1ccc(CC(NC(=O)C(NC(=O)C2C3CCN2C(=O)C(Cc2cn(Cc4cn(-c5cc(C)cc(C)c5)nn4)c4ccc(F)cc24)NC(=O)C(NC(=O)C(C)NC(=O)C(CNC(=O)CCOCCOCC[N+](C)(C)C)NC(=O)CCS)Cc2cccc(c2)CC=CCO3)C(C)O)C(=O)N2CCCC2(C)C(=O)NCCS)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: Participants received 12 mg of MK-0616 orally QD for 8 weeks
Eligibility criteria:
Inclusion Criteria:

History of clinical atherosclerotic cardiovascular disease (ASCVD), or has an ASCVD risk equivalent and/or a 10-year risk of having an ASCVD event ≥5.0%, AND has a corresponding LDL-C that falls within the protocol-specified range at screening.
Treatment with a stable dose of one or more lipid-lowering therapies for ≥30 days before screening, or has not received treatment with any lipid-lowering therapy for ≥30 days before screening.
A female participant is not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance during the intervention period and for at least 8 weeks after the last dose of study intervention.

Exclusion Criteria:

History of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria.
History of nephrotic syndrome.
History of unstable angina, a myocardial infarction, percutaneous transluminal coronary angioplasty, transient ischemic attack, or stroke within 3 months before Screening.
Has poorly controlled diabetes mellitus, defined as hemoglobin A1C (A1C) ≥9.0% at Screening.
History of malignancy ≤3 years before screening, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, which have no timeframe limitations relative to screening.
Currently participating in or has previously participated in an interventional clinical study within 3 months before Screening.
Has moderate or greater renal insufficiency.
Intervention: PCSK9 macrocyclic peptide inhibitor MK-0616
Trial phase: Phase 2
SMILES: COc1ccc(CC(NC(=O)C(NC(=O)C2C3CCN2C(=O)C(Cc2cn(Cc4cn(-c5cc(C)cc(C)c5)nn4)c4ccc(F)cc24)NC(=O)C(NC(=O)C(C)NC(=O)C(CNC(=O)CCOCCOCC[N+](C)(C)C)NC(=O)CCS)Cc2cccc(c2)CC=CCO3)C(C)O)C(=O)N2CCCC2(C)C(=O)NCCS)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: Participants received 18 mg of MK-0616 orally QD for 8 weeks
Eligibility criteria:
Inclusion Criteria:

History of clinical atherosclerotic cardiovascular disease (ASCVD), or has an ASCVD risk equivalent and/or a 10-year risk of having an ASCVD event ≥5.0%, AND has a corresponding LDL-C that falls within the protocol-specified range at screening.
Treatment with a stable dose of one or more lipid-lowering therapies for ≥30 days before screening, or has not received treatment with any lipid-lowering therapy for ≥30 days before screening.
A female participant is not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance during the intervention period and for at least 8 weeks after the last dose of study intervention.

Exclusion Criteria:

History of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria.
History of nephrotic syndrome.
History of unstable angina, a myocardial infarction, percutaneous transluminal coronary angioplasty, transient ischemic attack, or stroke within 3 months before Screening.
Has poorly controlled diabetes mellitus, defined as hemoglobin A1C (A1C) ≥9.0% at Screening.
History of malignancy ≤3 years before screening, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, which have no timeframe limitations relative to screening.
Currently participating in or has previously participated in an interventional clinical study within 3 months before Screening.
Has moderate or greater renal insufficiency.
Intervention: PCSK9 macrocyclic peptide inhibitor MK-0616
Trial phase: Phase 2
SMILES: COc1ccc(CC(NC(=O)C(NC(=O)C2C3CCN2C(=O)C(Cc2cn(Cc4cn(-c5cc(C)cc(C)c5)nn4)c4ccc(F)cc24)NC(=O)C(NC(=O)C(C)NC(=O)C(CNC(=O)CCOCCOCC[N+](C)(C)C)NC(=O)CCS)Cc2cccc(c2)CC=CCO3)C(C)O)C(=O)N2CCCC2(C)C(=O)NCCS)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: Participants received 30 mg of MK-0616 orally QD for 8 weeks
Eligibility criteria:
Inclusion Criteria:

History of clinical atherosclerotic cardiovascular disease (ASCVD), or has an ASCVD risk equivalent and/or a 10-year risk of having an ASCVD event ≥5.0%, AND has a corresponding LDL-C that falls within the protocol-specified range at screening.
Treatment with a stable dose of one or more lipid-lowering therapies for ≥30 days before screening, or has not received treatment with any lipid-lowering therapy for ≥30 days before screening.
A female participant is not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance during the intervention period and for at least 8 weeks after the last dose of study intervention.

Exclusion Criteria:

History of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria.
History of nephrotic syndrome.
History of unstable angina, a myocardial infarction, percutaneous transluminal coronary angioplasty, transient ischemic attack, or stroke within 3 months before Screening.
Has poorly controlled diabetes mellitus, defined as hemoglobin A1C (A1C) ≥9.0% at Screening.
History of malignancy ≤3 years before screening, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, which have no timeframe limitations relative to screening.
Currently participating in or has previously participated in an interventional clinical study within 3 months before Screening.
Has moderate or greater renal insufficiency.
Intervention: Opioid
Trial phase: Phase 3
SMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.CCOC(=O)C1(c2ccccc2)CCN(C)CC1.COc1ccc2c3c1OC1C(=O)CCC4(O)C(C2)N(C)CCC314
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: Received hydrocodone/acetaminophen
Eligibility criteria:
Inclusion Criteria:

Adult men and non-pregnant women who are at least 18 years of age, who are able to refrain from driving or operating heavy machinery while taking the study medication will be able to participate.
Subjects who are English speaking and are able to provide consent will be considered.
Subjects must be in generally good health and able to take ibuprofen, paracetamol (acetaminophen), and hydrocodone.

Exclusion Criteria:

Subjects who self-report the following history will be excluded from participating:

Individual under the age of 18
History of gastrointestinal bleeding and/or peptic ulcer
History of renal disease (excluding kidney stones)
History of hepatic disease
History of bleeding disorder
History of respiratory depression
Any prior respiratory effect of an opioid or other anesthetic drug that required respiratory support postoperatively
Active or untreated asthma
History of known allergic reaction to ibuprofen, acetaminophen, hydrocodone, and/or anesthesia

Currently taking any of the following medications:

CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), which may increase plasma concentrations of hydrocodone bitartrate and acetaminophen and prolong opioid adverse reactions, and which may cause potentially fatal respiratory depression
CNS depressants.
Consumes 3 or more alcoholic drinks every day and/or has a history of alcoholism
History of drug or alcohol abuse (excludes marijuana use)
Family history of drug or alcohol abuse in a first degree relative
Has had one or more opioid prescription filled within the past 6 months
Currently pregnant or lactating

Patients would also be excluded due to any additional criteria that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study which includes:

Prior participation in this study
Inability or refusal to provide informed consent
Intervention: Meloxicam
Trial phase: Phase 4
ATC code: M01AC06 | M01AC56 | N01BB59
SMILES: Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 19
Group description: N1539 (Meloxicam IV) 0.6 mg/kg (maximum 30 mg) Q24H

N1539: Once daily
Eligibility criteria:
Inclusion Criteria:

Male or female 2 to <17 years of age before dosing on Day 1
Eligible for elective surgery that will be performed according to standard surgical technique under appropriate anesthesia
Be premenarche or have confirmed negative urine pregnancy testing before surgery on Day 1, if an adolescent female of childbearing potential
Willing and able to cooperate with all the requirements of the study; including providing appropriate informed consent/assent

Exclusion Criteria:

Have a known allergy or hypersensitivity to meloxicam, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), or any excipient of N1539
Have a known bleeding disorder that may be worsened with the administration of an NSAID
Be undergoing cardiothoracic surgery
Has used meloxicam within 7 days before the surgical procedure on Day 1
Has any clinically significant medical history or clinical manifestations of significant disease or any other condition that increases the risk associated with the subject's participation in the study or compromises the scientific objectives of the study.
Intervention: Proparacaine
Trial phase: Phase 3
ATC code: S01HA04
SMILES: CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 61
Group description: 0.5% Proparacaine Hydrochloride

Proparacaine Ophthalmic: 0.5% Proparacaine Hydrochloride
Eligibility criteria:
Inclusion Criteria:

Pre-pubescent with no childbearing potential
Capable of undergoing an eye exam
Subject's legally appointed and authorized representative willing to sign and date an informed consent form (ICF) and, where appropriate, the subject willing to sign an assent form prior to any study-related procedures being performed.
Parent/legal guardian and subject are willing and able to follow instructions and can be present for the required study visits and Follow-up Phone Call for the duration of the study.
Have a healthy, normal cornea.

Exclusion Criteria:

Have participated in an investigational study (drug or device) within the past 30 days.
Have a known contraindication to local anesthetics.
Children with known autism spectrum disorders or known to have heightened sensitivity.
Corneal pathology that would make the corneal sensitivity lower/higher or make the test hard to perform or interpret.
Have low visual acuity
Manifest nystagmus
Have had ocular surgery or general surgery within the past 45 days.
Have had an intravitreal injection in either eye within 14 days of randomization.
Have ocular surface disease.
Intervention: Vimnerixin
Trial phase: Phase 2
SMILES: CC1CN(S(=O)(=O)Nc2cc(OC(C)C(O)CO)nc(SCc3ccc(F)cc3)n2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks

RIST4721: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Eligibility criteria:
Inclusion Criteria:

Diagnosis of HS for at least 1 year prior to screening
HS lesions must be present in at least 2 distinct anatomic areas
A total AN count (sum of abscesses and inflammatory nodules) > 6 across all anatomical sites at both the screening and baseline visits
Willing to use contraception for the duration of the study

Exclusion Criteria:

Presence of other skin conditions which may interfere with study assessments
Presence of active, chronic or latent bacterial, viral, fungal mycobacterial infection (including latent TB) or history of infection within 4 weeks of screening
Body Mass Index (BMI) >48kg/m2
Breastfeeding or pregnant
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 39
Group description: Dexamethasone ophthalmic insert, 0.4mg intracanalicular insert in the lower punctum on the day of surgery in the OR.
Eligibility criteria:
Inclusion Criteria:

Subjects will be eligible for study participation if they:

Are planning to undergo non-complicated CCI CE/PCIOL in one or both eyes with or without iStent/Hydrus/Goniotomy.
Are willing and able to comply with clinic visits and study related procedures.
Are willing and able to sign the informed consent form.
Not pregnant.

Exclusion Criteria:

Subjects are not eligible for study participation if they:

Are currently being treated with corticosteroid implant (i.e. Ozurdex).
Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye.
Have a history of complete punctal occlusion in one or both punctum.
Currently use topical ophthalmic steroid medications.
Are unwilling or unable to comply with the study protocol.
Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) or if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment.
Have active infectious systemic disease.
Have active infectious ocular or extraocular disease.
Have unobstructed nasolacrimal duct in the study eye(s) (dacrocystitis).
Have known hypersensitivity to dexamethasone or are a known steroid responder.
Have a history of ocular inflammation or macular edema.
Are currently being treated with immunomodulating agents in the study eye(s).
Are currently being treated with immunosuppressants an/or oral steroids.
Are Pregnant or breast-feeding or wish to become pregnant during the length of study participation.